Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients

Lim, EHT; Vlaar, APJ; de Bruin, S; Rückinger, S; Thielert, C; Habel, M; Guo, RF; Burnett, BP; Dickinson, J; Brouwer, MC; Riedemann, NC; van de Beek, D

Lim, EHT (通讯作者)，Univ Amsterdam, Dept Intens Care Med, Amsterdam UMC, AMC Room C3-421,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.;Lim, EHT (通讯作者)，Univ Amsterdam, Dept Neurol, Amsterdam UMC, Meibergdreef 9, Amsterdam, Netherlands.

INTENSIVE CARE MEDICINE EXPERIMENTAL, 2023; 11 (1):

Abstract

Background: Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients in a phase 3 multic......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索